Clinical outcomes of abiraterone acetate (AA) or enzalutamide (E) as first-line therapy (Rx) for men aged ≥75 with metastatic castration-resistant prostate cancer (mCRPC) according to previous use of docetaxel (D) for metastatic castration-sensitive prostate cancer (mCSPC) in a multicenter international registry: A SPARTACUSS – Meet-URO 26 study.

Authors

null

Richard M. Lee-Ying

Tom Baker Cancer Centre, Calgary, AB, Canada

Richard M. Lee-Ying , Calogero Saieva , Pier Vitale Nuzzo , Andrea Malgeri , Giuseppe Fotia , Elisa Zanardi , Sabrina Rossetti , Loana Bueno Valenca , Anna Patrikidou , Mikol Modesti , Thiago Martins Oliveira , Sandro Pignata , Giuseppe Fornarini , Giuseppe Procopio , Daniele Santini , Christopher Sweeney , Daniel Yick Chin Heng , Ugo De Giorgi , Antonio Russo , Edoardo Francini

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Prostate Cancer and Urothelial Carcinoma

Track

Urothelial Carcinoma,Prostate Cancer - Advanced

Sub Track

Quality of Care/Quality Improvement and Real-World Evidence

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr 107)

DOI

10.1200/JCO.2023.41.6_suppl.107

Abstract #

107

Poster Bd #

D20

Abstract Disclosures

Similar Posters